Nahome Fisseha
ABB (Japan)(JP)AbbVie (Japan)
Publications by Year
Research Areas
Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Attention Deficit Hyperactivity Disorder
Most-Cited Works
- → Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial(2022)177 cited
- → Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial(2021)134 cited
- → Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study(2023)121 cited
- → Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance(2024)31 cited
- Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization.(2021)
- → Identifying predictive factors of patient dropout in Alzheimer’s disease clinical trials(2021)5 cited
- → Safety of Foslevodopa/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial (S32.004)(2023)3 cited
- → Efficacy and safety of foslevodopa/foscarbidopa versus oral carbidopa/levodopa in advanced Parkinson's disease patients: Design of a phase 3, randomized, double-blind, double-dummy, active controlled 12-week trial(2021)2 cited
- → Baseline amyloid and tau PET imaging characteristics in the ongoing phase 2 study of tilavonemab in early Alzheimer’s disease(2021)
- → Efficacy and Safety of Foslevodopa/Foscarbidopa Versus Oral Carbidopa/Levodopa in Advanced Parkinson’s Disease Patients: Design of a Phase 3, Randomized, Double-Blind, Double-Dummy, Active Controlled 12-Week Trial (2251)(2021)